Allergy Asthma Immunol Res.
2015 Mar;7(2):158-166. 10.4168/aair.2015.7.2.158.
Comparison of Intranasal Ciclesonide, Oral Levocetirizine, and Combination Treatment for Allergic Rhinitis
- Affiliations
-
- 1Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Korea. jhyoon@yuhs.ac
- 2Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, Konkuk University, Seoul, Korea.
- 3Department of Otolaryngology, Ajou University School of Medicine, Suwon, Korea.
- 4Department of Otorhinolaryngology-Head and Neck Surgery, The Catholic University of Korea, Seoul, Korea.
- 5Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, Kyungpook National University, Daegu, Korea.
- 6Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, Yeungnam University, Daegu, Korea.
- 7Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine, Seoul, Korea.
- 8Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Kyunghee University, Seoul, Korea.
- 9Department of Otorhinolaryngology, Pusan National University School of Medicine, Busan, Korea.
- 10Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul, Korea.
- 11Department of Otorhinolaryngology-Head and Neck Surgery, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 12Department of Otolaryngology, Chungnam National University School of Medicine, Daejeon, Korea.
- KMID: 2365544
- DOI: http://doi.org/10.4168/aair.2015.7.2.158
Abstract
- PURPOSE
To evaluate the efficacy and safety of once-daily ciclesonide in comparison to both levocetirizine alone, and a ciclesonide/levocetirizine combination in patients with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).
METHODS
Subjects exhibiting moderate to severe allergic rhinitis for longer than 1 year were randomized in an open-label, 3-arm, parallel group, multicenter study. Subjects received 200 microg ciclesonide, 5 mg levocetirizine, or a combination of both. Changes from baseline until the end-of-study visit (2 weeks following) were evaluated by reflective total nasal symptom scores (rTNSSs), reflective total ocular symptom scores (rTOSSs), physician-assessed overall nasal signs and symptoms severity (PANS), and rhinoconjunctivitis quality-of-life questionnaires (RQLQ).
RESULTS
Significant improvements in rTNSS, PANS, and RQLQ in the ciclesonide monotherapy group were observed in comparison to the levocetirizine alone group. Three individual symptoms of rTNSS, including runny nose, nasal itching, and congestion, were improved in the ciclesonide-treated group. rTOSS scores for ciclesonide monotherapy improved from baseline, but no superiority over levocetirizine was shown. The absolute score and changes in rTNSS and PANS were positively correlated. Ciclesonide spray was more effective than levocetirizine in reducing nasal symptoms in both SAR and PAR patients. Ciclesonide and levocetrizine were well tolerated alone and in combination.
CONCLUSIONS
Our results provide support for an AR and its Impact on Asthma (ARIA) recommendation stipulating that ciclesonide is superior to levocetirizine for the treatment of AR, with tolerable safety. Addition of levocetirizine to ciclesonide did not give further clinical benefit over monotherapy.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Update on pediatric allergic rhinitis: narrative review based on guideline updates
- Effect of Proparacaine in a Mouse Model of Allergic Rhinitis
- Effects of Levocetirizine on Quality of Life in the Patients with Allergic Rhinitis
- Prevalence, comorbidities, diagnosis, and treatment of nonallergic rhinitis: real-world comparison with allergic rhinitis
- Evidences for Local Allergic Rhinitis
